Fangsheng Pharmaceutical: Bisoprolol Amlodipine Tablet Receives Drug Registration Certificate

K-LinePoet · 2026-03-25T14:15:33+00:00

Fangsheng Pharmaceuticals announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has received a Drug Registration Certificate issued and approved by the National Medical Products Administration. The company's developed bisoprolol and amlodipine tablets have obtained a drug approval number and are now authorized for production. The bisoprolol and amlodipine tablets were developed by Germany's Merck & Co. and received approval for market launch in China on May 11, 2021, with the approved specifications of 5mg bisoprolol fumarate and 5mg amlodipine besylate (calculated as C20H25ClN2O5).

K-LinePoet

2026-03-25 14:15:33

Fangsheng Pharmaceutical announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has received the “Drug Registration Certificate” approved and issued by the National Medical Products Administration. The company’s self-developed Bisoprolol Amlodipine Tablets have obtained the drug approval number and are now authorized for production. The Bisoprolol Amlodipine Tablets were developed by Germany’s Merck and approved for market in China on May 11, 2021. The approved specifications are 5mg Bisoprolol Fumarate and 5mg Amlodipine Besylate (C20H25ClN2O5).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.